BPOM urges optimisation of domestic drug production to address global pressures

Jakarta (ANTARA) - The National Agency of Drug and Food Control (BPOM) is urging the optimisation of domestic drug production capacity as a mitigation measure to address the impacts of the conflict between Iran and the United States-Israel, which could lead to export limitations and rising drug prices.

“Recommendations and mitigation steps by the POM Agency have been implemented, namely technology-based supervision and optimisation of production capacity,” said BPOM Head Taruna Ikrar during a hearing with Commission IX of the House of Representatives (DPR RI) in Jakarta on Monday.

Furthermore, in the presentation delivered by Taruna Ikrar at the meeting, it was stated that efforts to promote the optimisation of national drug production capacity are being carried out through coordination with the Ministry of Health (Kemenkes), particularly regarding generic drugs.

In crisis conditions, the government is encouraging temporary restrictions on the production of branded generic drugs so that industrial capacity can be focused on meeting the needs of essential drugs for the public.

This step is part of a strategy to maintain drug availability amid global pressures, while also curbing the potential for price surges due to supply chain disruptions and rising production costs.

BPOM is also strengthening hybrid technology-based supervision, which includes evaluation, certification, and inspections through collaboration with ministries/institutions and the pharmaceutical industry.

Another measure being pursued is the utilisation of fast-track import channels through the Special Access Scheme (SAS) mechanism to accelerate the drug import process and ensure national availability.

In addition, the government is considering adjustments to drug prices, particularly those based on petrochemical materials, in line with increasing global production cost pressures.